Fig. 3From: Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective studyPFS in patients with and without HbL increase ≥2.3 g/dL during the first three months of axitinib treatment (a). PFS in patients with HbL increase ≥2.3 g/dL combined with hBP and with either or no factors (b). HbL: haemoglobin level; hBP: high blood pressure; mo.: monthsBack to article page